EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Multivalent Atezolizumab-Liposome Conjugates as Active Immunotherapeutic Platforms for Enhanced PD-L1 Blockade in Melanoma

Ziyun Cheng iD, Mohamadreza Amin iD, Mandy van Brakel iD, Andrea Sacchetti iD, Robbert Q Kim iD, Ann L B Seynhaeve iD, Reno Debets iD, Timo L M Ten Hagen iD

International Journal of Nanomedicine · 2026-01 · Volume 21 · 1-22

DOI: 10.2147/ijn.s561111 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Nanomedicine, 2026-01. Verfasst von Ziyun Cheng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Precision Medicine in Oncology (PrMiO) and Nanomedicine Innovation Center Erasmus (NICE), Department of Pathology, Erasmus MC Cancer Institute, Erasm…. Hauptthemen laut MEDLINE: Liposomes, Melanoma, B7-H1 Antigen, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LiposomesMelanomaB7-H1 AntigenAntibodies, Monoclonal, HumanizedHumansCell Line, TumorImmunotherapyAntibodies, Monoclonal

Stichwörter der Autor:innen

anti-PD-L1 mAbcancer immunotherapyimmune checkpoint inhibitorsliposomesmelanomatargeted drug delivery

Substanzen

LiposomesB7-H1 AntigenAntibodies, Monoclonal, HumanizedatezolizumabCD274 protein, humanAntibodies, Monoclonal

Autor:innen und Institutionen

  • Precision Medicine in Oncology (PrMiO) and Nanomedicine Innovation Center Erasmus (NICE), Department of Pathology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, the Netherlands.
  • Laboratory of Tumor Immunology, Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, the Netherlands.
  • Department of Pathology, Erasmus MC, Rotterdam, the Netherlands.
  • Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands.

ORCID-Profile: Ziyun Cheng, Mohamadreza Amin, Mandy van Brakel, Andrea Sacchetti, Robbert Q Kim, Ann L B Seynhaeve, Reno Debets, Timo L M Ten Hagen

Zitieren

APA

Cheng, Z., Amin, M., van Brakel, M., Sacchetti, A., Kim, R. Q., Seynhaeve, A. L. B., Debets, R., & Ten Hagen, T. L. M. (2026). Multivalent Atezolizumab-Liposome Conjugates as Active Immunotherapeutic Platforms for Enhanced PD-L1 Blockade in Melanoma. International Journal of Nanomedicine, Volume 21, 1-22. https://doi.org/10.2147/ijn.s561111

Vancouver

Cheng Z, Amin M, van Brakel M, Sacchetti A, Kim RQ, Seynhaeve ALB, et al. Multivalent Atezolizumab-Liposome Conjugates as Active Immunotherapeutic Platforms for Enhanced PD-L1 Blockade in Melanoma. International Journal of Nanomedicine. 2026;Volume 21:1-22. doi:10.2147/ijn.s561111

BibTeX
@article{Cheng2026,
  author = {Cheng, Ziyun and Amin, Mohamadreza and van Brakel, Mandy and Sacchetti, Andrea and Kim, Robbert Q and Seynhaeve, Ann L B and Debets, Reno and Ten Hagen, Timo L M},
  title = {Multivalent Atezolizumab-Liposome Conjugates as Active Immunotherapeutic Platforms for Enhanced PD-L1 Blockade in Melanoma},
  journal = {International Journal of Nanomedicine},
  year = {2026},
  volume = {Volume 21},
  pages = {1--22},
  doi = {10.2147/ijn.s561111}
}
Kostenlos starten →